// App-Quantinova.ai

: RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS ON FIRST LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER: A COMPARISON OF IMMUNE CHECKPOINT INHIBITORS AND CHEMOTHERAPY REGIMENS

Researchers

Presenter

  • Alok Khorana

Principal Investigators

  • Lisa Rosenblatt

  • Radhika Pisupati

  • Chi Nguyen

  • John Barron

  • Kerrin Gallagher

  • Jennell Palaia

  • T. Christopher Bond

Medical Centers

  • Cleveland Clinic, Cleveland, OH

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Oncology (ONC)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Non Small Cell Lung cancer

  • Venous thrombosis

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved